In an article published in Expert Opinion on Pharmacotherapy, Dr. Alanna Nattis outlined how the first medication approved in the United States for the treatment of signs and symptoms of Dry Eye Disease (Lifitegrast) fits into today’s treatment regime for Dry Eye Disease. Dr. Nattis pointed out that DED is a common ocular surface disorder that can have a major negative impact on the quality of life and our normal daily activities. The purpose of Dr. Nattis’ article was to summarize the preclinical and clinical data on Lifitegrast and discuss the effectiveness of Lifitegrast ophthalmic solution 5.0% had on patients suffering from Dry Eye Disease. In her conclusion, Dr. Nattis reported that during clinical trials conducted in adults with DED, Lifitegrast ophthalmic solution 5.0% improved both signs and symptoms of DED. Future research should include an evaluation of whether Lifitegrast can be used in combination with other DED treatments. =
To read the complete article, please click this link.